MK-677 vs Ipamorelin
Side-by-side comparison of MK-677, Ipamorelin — mechanism, dosing, half-life, side effects, and research status.
| Attribute | MK-677 MK-677 (Ibutamoren) — Oral GH Secretagogue Growth Hormone | Ipamorelin Ipamorelin (Selective GHRP) Growth Hormone |
|---|---|---|
| Basics | ||
| Molecular type | Non-Peptide GH Secretagogue | Growth Hormone Releasing Peptide (GHRP) |
| Amino acids | — | 5 |
| Molecular weight | 624.8 Da | 711.9 Da |
| Half-life | ~24 hours | ~2 hours |
| Route(s) | Oral | Subcutaneous, Intramuscular |
| Mechanism & Research | ||
| Primary mechanism | MK-677 mimics ghrelin's binding to GHSR-1a receptors, activating the same signalling cascade that endogenous ghrelin uses to stimulate GH release. As a small non-peptide molecule, it resists enzymatic degradation and is … | Ipamorelin activates growth hormone secretagogue receptors (GHSR-1a) in the pituitary, triggering pulsatile GH release. Unlike first-generation GHRPs (GHRP-6, GHRP-2), ipamorelin's selectivity for GHSR-1a is high enough … |
| Research status | Research Compound | Research Compound |
| Evidence summary | MK-677 has one of the most extensive clinical datasets of any non-approved GH secretagogue, with Phase 1/2 trials across multiple populations including GH-deficient adults, elderly frail patients, and post-hip-fracture p… | Ipamorelin was among the first highly selective GHRPs to enter research. Phase 1 trials confirmed its clean hormonal profile. It remains a reference GHRP in comparative studies and is widely used as the GHRP component in… |
| Protocol & Dosing | ||
| Typical dose | 10–25 mg/day | 100–300 mcg per injection |
| Frequency | Once daily | 2–3x daily (or 1x at bedtime) |
| Duration | 8–16 weeks; some protocols run 6 months | 8–12 weeks on, 4 weeks off |
| Timing | Bedtime (maximises nocturnal GH pulse; also reduces daytime appetite impact) | Fasted state or 2+ hours post-meal for maximum GH response; bedtime dosing utilises natural nocturnal GH pulse |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Prohibited (WADA S2) | Prohibited (WADA S2) |
| Deeper reading | ||
| Related peptides | Ipamorelin, CJC-1295, GHRP-6 | CJC-1295, GHRP-2, Sermorelin, Tesamorelin |
| Full profile | Read full MK-677 profile → | Read full Ipamorelin profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.